Research programme: dianexin based therapeutics - Lawson Health Research Institute/Yabao Pharmaceuticals

Drug Profile

Research programme: dianexin based therapeutics - Lawson Health Research Institute/Yabao Pharmaceuticals

Alternative Names: Annexin A5 based therapeutics - Lawson Health Research Institute/Yabao Pharmaceuticals

Latest Information Update: 06 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lawson Health Research Institute; Yabao Pharmaceutical Group
  • Class Biological peptides; Calcium binding proteins; Recombinant fusion proteins
  • Mechanism of Action Phosphatidylserine receptor modulators; Phospholipase A2 inhibitors; Urokinase-type plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Sepsis

Most Recent Events

  • 24 Jul 2014 Yabao Pharmaceuticals entered into an exclusive license agreement with Lawson Health Research Institute to discover, develop and commercialise products based on dianexin for Sepsis in China, Taiwan and Hong Kong
  • 01 Jul 2014 Preclinical trials in Sepsis in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top